chevron_leftBack
As of 16 June 2026, Santhera Pharmaceuticals Holding AG has a market cap of $322.94M USD, ranking #18134 globally and #185 in Switzerland.
It ranks #1648 in the Healthcare sector, and #597 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$322.94MUSD
258.2M CHF
Enterprise Value
$356.1MUSD
284.71M CHF
Revenue (TTM)
$96.54MUSD
77.19M CHF
EBITDA (TTM)
-$39.94MUSD
-31.93M CHF
Net Income (TTM)
-$61.58MUSD
-49.24M CHF
EBITDA Margin
-41%
Profit Margin
-64%
Forward PE
206.0
PS Ratio
3.3
PB Ratio
-21.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dario Eklund
open_in_new
Employees
78
Founded
2004
Website
santhera.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.6% | 8.4% | 22% | 43% | 75% | 25% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SANN
ISIN: CH1276028821
Shares Out.:
Shares Outstanding:
14.835M1
Shares Float:
11.611M2
|
18.06 CHF | |
|
0QN1
ISIN: CH1276028821
|
18.56 CHF | |
|
SPHDF
ISIN: CH1276028821
Shares Out.:
Shares Outstanding:
12.949M1
Shares Float:
10.073M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
18.40 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$320.51B
99K%
256.25B CHF
|
19.9
|
|
SIX: NOVN
|
$273.78B
85K%
218.9B CHF
|
20.5
|
|
SIX: GALD
|
$46.43B
14K%
37.12B CHF
|
77.4
|
|
SIX: SDZ
|
$33.91B
10K%
27.11B CHF
|
37.8
|
|
SSE: 688235
|
$32.64B
10K%
220.98B CNY
|
110.1
|
|
SIX: BANB
|
$6.39B
2K%
5.11B CHF
|
34.3
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
236K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
169K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
112K%
|
97.4
|
|
LSE: AZN
|
$288.14B
89K%
215.59B GBP
|
27.6
|
|
NYSE: MRK
|
$274.03B
85K%
|
15.1
|
|
CPH: NOVO-B
|
$181.97B
56K%
1.18T DKK
|
11.5
|
chevron_leftBack